Archives
FDA Okays Gilead's $1,000-a-day Drug for Hepatitis C
The U.S. Food and Drug Administration has okayed Gilead Sciences Inc's Sovaldi for the treatment of chronic hepatitis C virus (HCV) infection.
Latest Research Articles
FDA Approves Xiaflex for Peyronie’s disease
Deforestation May Offer Climate, Economic Benefits in Certain Areas
Primate Eating Habits Revealed in First In-depth Analysis
Global Fishing Meeting Ends in 'Failure' to Protect Tuna
New Fossilized Vertebrate a First for Mozambique
Largest Fault Slip Ever Recorded Generated Tohoku Earthquake and Tsunami
Most of Stranded Pilot Whale Group in Florida Not Located in Aerial Search
Large Freshwater Reserves Buried Beneath Oceans
Healthy Diet Costs $550 More per Year: Harvard Study
Poor Brain Wiring Behind Dyslexia
Nerves in Stomach Control Eating Habits
Scientists Predict Sea Level Rise on New Jersey Coast will be Well Above Global Average
MOST POPULAR
-
How Gene Editing Could Save Endangered Species from Extinction
-
Florida Teen Survives Alligator Attack by 'Punching It in the Head'
-
Millionaire CEO Trampled to Death By His Own Elephant on South African Game Reserve
-
Met Office Issues Warning About Thunderstorms And Flooding: Are They Coming To A Place Near You?
-
Greta Thunberg's Gaza Flotilla Fire Not Caused by Drone, Tunisia Says
